Profile data is unavailable for this security.
About the company
Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.
- Revenue in NOK (TTM)108.19m
- Net income in NOK7.00m
- Incorporated1995
- Employees68.00
- LocationArcticzymes Technologies ASASykehusveien 23TROMSO 9019NorwayNOR
- Phone+47 77648900
- Fax+47 77648901
- Websitehttps://arcticzymes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cantargia AB | 0.00 | -231.77m | 363.28m | 23.00 | -- | 3.89 | -- | -- | -1.29 | -1.29 | 0.00 | 0.4932 | 0.00 | -- | -- | 0.00 | -98.38 | -55.08 | -129.99 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -26.76m | 384.24m | 3.00 | -- | 13.61 | -- | -- | -0.4796 | -0.4796 | 0.00 | 0.5248 | 0.00 | -- | -- | 0.00 | -65.39 | -68.27 | -73.28 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -42.52m | 407.90m | 7.00 | -- | -- | -- | -- | -0.2756 | -0.2756 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -80.47 | -- | -97.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -104.57 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -143.79m | 512.03m | 28.00 | -- | 0.7211 | -- | -- | -3.54 | -3.54 | 0.00 | 13.87 | 0.00 | -- | -- | 0.00 | -21.08 | -18.84 | -23.01 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0318 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Alligator Bioscience AB | 28.19m | -252.46m | 535.66m | 47.00 | -- | -- | -- | 19.00 | -0.3667 | -0.3667 | 0.0403 | -0.1001 | 0.201 | -- | 9.80 | 478,017.30 | -180.01 | -73.26 | -2,941.13 | -91.33 | -- | -- | -895.60 | -811.68 | -- | -27.01 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Promimic AB | 41.60m | -10.62m | 671.53m | 17.00 | -- | 9.31 | -- | 16.14 | -0.563 | -0.563 | 2.21 | 3.80 | 0.4828 | -3.88 | 3.92 | 2,406,824.00 | -12.33 | -24.89 | -14.16 | -29.25 | 104.60 | 101.23 | -25.54 | -89.47 | 4.51 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Intellego Technologies AB | 235.12m | 84.25m | 681.90m | 62.00 | 8.40 | 3.10 | 7.41 | 2.90 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Arcticzymes Technologies ASA | 108.19m | 7.00m | 701.72m | 68.00 | 100.53 | 2.20 | 54.02 | 6.49 | 0.1367 | 0.1367 | 2.10 | 6.24 | 0.3199 | 0.45 | 1.93 | 1,591,059.00 | 2.07 | 15.58 | 2.19 | 17.22 | 93.99 | 96.69 | 6.47 | 33.23 | 14.95 | -- | 0.0273 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Nykode Therapeutics ASA | 67.60m | -416.96m | 793.78m | 179.00 | -- | 0.4746 | -- | 11.74 | -1.34 | -1.34 | 0.2114 | 5.12 | 0.0333 | -- | 1.59 | 390,764.40 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
Data as of Nov 08 2024. Currency figures normalised to Arcticzymes Technologies ASA's reporting currency: Norwegian Krone NOK
9.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 2023 | 1.59m | 3.11% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 830.00k | 1.63% |
| Aktia Bank Plc (Investment Management)as of 30 Sep 2024 | 500.00k | 0.98% |
| Didner & Gerge Fonder ABas of 30 Jun 2024 | 465.00k | 0.91% |
| DNB Asset Management ASas of 30 Aug 2024 | 419.72k | 0.82% |
| 10xDNA Capital Partners GmbHas of 30 Sep 2024 | 255.36k | 0.50% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 217.94k | 0.43% |
| Equinor Asset Management ASAas of 28 Jun 2024 | 204.44k | 0.40% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 185.64k | 0.36% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 175.00k | 0.34% |
More ▼
Data from 28 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
